BOSTON ( TheStreet) -- Welcome to July's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 60 minutes or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

We're about to start second-quarter earnings season, so let's discuss the outlook for some of the large-cap biotech stocks like Gilead Sciences ( GILD), Celgene ( CELG) and Biogen Idec ( BIIB).

New drug launches are a big theme for the second-quarter earnings season. For this reason, investors are closely tracking Human Genome Sciences ( HGSI), Vertex Pharmaceuticals ( VRTX), Dendreon ( DNDN) and Avanir Pharma ( AVNR). I have some insight into expectations for the quarter.

On Thursday, Transcept Pharmaceuticals ( TSPT) received its second FDA rejection letter for a sleeping pill while Seattle Genetics ( SGEN) nailed two positive recommendations from an FDA advisory panel for its experimental cancer drug. Regulatory issues are a big part of biotech investing, so we can hash out the issues.

The numbers don't work for Adventrx Pharmaceuticals ( ANX), as I point out in today's Biotech Stock Mailbag, but I'm open for a debate.

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.